RxDoctor Payments Data

Kenneth Wogensen, MD

Neurology · Arcadia, CANPI 1932109295

Payments from drug & device makers

$26,541in general payments, 2019–2025

Across 1,265 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • Biogen$2K
  • AbbVie$2K
  • Novartis$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • AstraZeneca$1K
  • plus $15K from 54 others

What the payments were for

  • Speaking & faculty fees$760%
  • Food & beverage$25,94298%
  • Education$5232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.124$2,215
Biogen86$2,160
AbbVie(2 entities)109$2,049
Novartis117$1,805
Teva Pharmaceuticals USA, Inc.60$1,670
AstraZeneca(2 entities)58$1,418
Acadia Pharmaceuticals Inc69$1,386
Eisai Inc.38$1,125
Amgen(2 entities)47$946
Lilly USA, LLC56$928
Pfizer43$894
Sanofi34$719
Amneal Pharmaceuticals LLC27$586
Lundbeck LLC26$563
EMD Serono, Inc.25$486
Sunovion Pharmaceuticals Inc.25$467
MDD US Operations, LLC17$428
Neurocrine Biosciences, Inc.16$424
Jazz Pharmaceuticals Inc.15$412
Bristol Myers Squibb20$398
Grifols USA, LLC10$381
Avanir Pharmaceuticals, Inc.16$331
Acorda Therapeutics, Inc11$245
Ipsen Biopharmaceuticals, Inc9$243
Alnylam Pharmaceuticals Inc.10$231
Biohaven Pharmaceutical Holding Company Ltd.12$229
Greenwich Biosciences, Inc.9$215
Merz Pharmaceuticals, LLC6$214
SK Life Science, Inc.17$208
Otsuka America Pharmaceutical, Inc.10$208
Abbott8$197
CSL Behring10$189
Aquestive Therapeutics, Inc.7$129
Biohaven Pharmaceuticals, Inc.5$127
Takeda Pharmaceuticals U.S.A., Inc.8$121
Corium, LLC6$119
Adamas Pharmaceuticals, Inc.6$117
Almatica Pharma LLC5$117
Supernus Pharmaceuticals, Inc.5$107
Kyowa Kirin, Inc.6$106
Catalyst Pharmaceuticals, Inc.5$105
Genentech USA, Inc.3$97
Argenx US, Inc.4$96
Johnson & Johnson(2 entities)5$95
TG Therapeutics, Inc.3$94
Zyla Life Sciences, Inc.5$84
Mallinckrodt Hospital Products Inc.3$82
Cycle Pharmaceuticals Inc3$81
Neurelis, Inc.4$75
Zogenix Inc.3$65
Octapharma USA, Inc.2$60
Immedica Pharma US, Inc.2$56
Tanabe Pharma America, Inc.3$55
Medtronic(2 entities)3$55
Vertical Pharmaceuticals, LLC3$49
Mallinckrodt Enterprises LLC2$48
Akcea Therapeutics, Inc.2$43
Impel Pharmaceuticals Inc.2$38
Livanova USA, Inc.1$35
Assertio Therapeutics, Inc.2$31

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,541 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$707,002
Medicare patients
750
Services billed
84,881

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5047$659,398
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$385,596
Kesimpta PenOfatumumab22$242,697
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5022$192,954
XyremSodium Oxybate15$162,274
Avonex (4 Pack)Interferon Beta-1a14$113,729
NuedextaDextromethorphan Hbr/Quinidine44$69,515
AptiomEslicarbazepine Acetate16$61,189
Lacosamide53$16,441
UbrelvyUbrogepant14$15,380
EliquisApixaban27$15,079
BotoxOnabotulinumtoxina11$11,920
Levetiracetam224$10,340
NucyntaTapentadol Hcl11$9,975
Carbamazepine ErCarbamazepine52$6,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$189$659,39847 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$121$385,59613 claims
BiogenAvonex (4 Pack)$2,160$113,72914 claims
Avanir Pharmaceuticals, Inc.Nuedexta$331$69,51544 claims
Sunovion Pharmaceuticals Inc.Aptiom$467$61,18916 claims
AbbVieUbrelvy, Botox$2,049$27,30025 claims
PfizerEliquis$894$15,07927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →